FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with 160+ patents, announced its participation at The German-Nordic Joint Extracellular Matrix Meeting in Freiburg, Germany (March 26-28, 2025). Dr. Hamid Khoja, Chief Scientific Officer, will present on the company's fibroblast cell-based approach for treating chronic diseases.
The presentation, titled 'Potential Treatment of Chronic Diseases With the Aim of Immune System Homeostasis Rather Than Depletion or Over-activation', will take place on March 27, 2025, from 10:25 a.m. to 12:00 p.m. Central European Time at Otto-Krayer Haus.
FibroBiologics specializes in developing therapeutics using fibroblasts and fibroblast-derived materials, with applications across multiple conditions including:
- Disc degeneration
- Orthopedics
- Multiple sclerosis
- Psoriasis
- Wound healing
- Organ involution reversal
- Cancer
Positive
- None.
Negative
- None.
News Market Reaction – FBLG
In the trading session that priced this news, FBLG gained 7.77%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment of chronic diseases at The German-Nordic Joint Extracellular Matrix Meeting in Freiburg, Germany, from March 26-28, 2025. The joint meeting is an annual opportunity to showcase advances in extracellular matrix biology.
Dr. Khoja commented, “Fibroblasts are a critical component of the extracellular matrix with regenerative and immunomodulatory properties. Our presentation will detail the progress we’ve made in expanding our portfolio and targeting additional indications by leveraging the unique potential of fibroblasts.”
Details of the conference and presentations are as follows:
The German-Nordic Joint Extracellular Matrix Meeting
Presentation Title: Potential Treatment of Chronic Diseases With the Aim of Immune System Homeostasis Rather Than Depletion or Over-activation.
Presenter: Hamid Khoja, Ph.D., Chief Scientific Officer, FibroBiologics
Location: Otto-Krayer Haus, Albertstrasse 25, Freiburg, Germany
Date and Time: Thursday, March 27, at 10:25 a.m. to 12:00 p.m. Central European Time
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
